Is Lineage Cell Therapeutics Inc (LCTX) overvalued? · rev $9.5M
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
This page asks whether Lineage Cell Therapeutics Inc (LCTX) looks expensive on cached numbers — not a short thesis.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
LCTX currently screens at market cap $213.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LCTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LCTX stock page for the full model, not this heading.
Not investment advice.